Cardiovascular risk factors in chronic Chagas' disease are associated with a different profile of putative heart-pathogenic antibodies

FEMS Immunology and Medical Microbiology

Volumn 48, Issue 1, 2006, Pages 26-33

  Diez, Cristina ^a   Gea, Susana ^b   Marcipar, Iván ^a   Pezzotto, Stella Maris ^c   Beloscar, Juan ^c   Pellizzon, Oscar ^c   Marcipar, Alberto ^a   Bottasso, Oscar ^c  

^a UNIVERSIDAD NACIONAL DEL LITORAL   (Argentina)

^b UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^c FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

Author keywords

Cardiovascular risk factors; Chagas' disease; Crossreactive antibodies; Heart damage

Indexed keywords

ANTIGEN; CRUZIPAIN;

ADULT; ANTIBODY RESPONSE; ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CHAGAS DISEASE; CHRONIC DISEASE; CONTROLLED STUDY; ELECTROCARDIOGRAM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELIN SHEATH; PRIORITY JOURNAL; SEROLOGY; THORAX RADIOGRAPHY; TRYPANOSOMA CRUZI;

ANIMALS; CARDIOVASCULAR DISEASES; CHAGAS CARDIOMYOPATHY; CHAGAS DISEASE; CHRONIC DISEASE; RISK FACTORS; TRYPANOSOMA CRUZI;

EID: 33748615479     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2006.00115.x     Document Type: Article

References (42)

1. Andrade Z (1999) Immunopathology of Chagas' disease. Mem Inst Oswaldo Cruz 94: 71-80.
2. Avila JL, Rojas M & Carrasco H (1993) Elevated levels of antibodies against sulphatide are present in all chronic chagasic and non-chagasic dilatatory cardiomyopathy sera. Clin Exp Immunol 92: 460-465.
3. Aznar C, Lopez-Bergami P, Brandariz S, et al. (1995) Prevalence of anti-R-13 antibodies in human Trypanosoma cruzi infection. FEMS Immunol Med Microbiol 12: 231-238.
4. Berra H, Carnevali F, Revelli S, Moreno H, Pezzotto SM, Morini JC & Bottasso OA (1998) Electrocardiographic alterations in chronically Trypanosoma cruzi-infected persons exposed to cardiovascular risk factors. Arch Med Res 29: 241-246.
5. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
6. Brener Z & Gazzinelli RT (1997) Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas' disease. Int Arch Allergy Immunol 114: 103-110.
7. Cruz-Robles D, Reyes PA, Monteón-Padilla VM, Ortiz-Muñiz AR & Vargas-Alarcón G (2004) MHC class I and class II genes in Mexican patients with Chagas disease. Hum Immunol 65: 60-65.
8. Dávila H, Beloscar JS, Bottasso OA & Morini JC (1987) Alteraciones electrocardiográficas en individuos infectados con Tripanosoma cruzi con distintos tiempos de residencia en áreas de alta endemicidad. Medicina (Buenos Aires) 47: 154-158.
9. De Lederkremer R, Zingales B, Confalonieri A, Couto A, Martin N & Colli W(1985) In vivo incorporation of palmitic acid and galactose in glycolipids of Trypanosoma cruzi epimastigotes. Biochem Int 10: 78-88.
10. Duschak VG, Riarte A, Segura EL & Laucella SA (2001) Humoral immune response to cruzipain and cardiac dysfunction in chronic Chagas disease. Immunol Lett 78: 135-142.
11. Feldman S, García G, Svetaz MJ, Avila JL, Revelli S, Bottasso OA & Marcipar A (1999) Evidence that antisulphatide autoantibodies from experimentally Trypanosoma cruzi-infected rats bind to homologous neural tissue. Parasitol Res 85: 446-451.
12. Giordanengo L, Fretes R, Diaz H, Cano R, Bacile A, Vottero-Cima E & Gea S (2000a) Cruzipain induces autoimmune response against skeletal muscle and tissue damage in mice. Muscle Nerve 23: 1407-1413.
13. Giordanengo L, Maldonado C, Rivarola HW, Iosa D, Girones N, Fresno M & Gea S (2000b) Induction of antibodies reactive to cardiac myosin and development of heart alterations in cruzipain-immunized mice and their offspring. Eur J Immunol 30: 3181-3189.
14. Girones N & Fresno M (2003) Etiology of Chagas disease myocarditis:autoimmunity, parasite persistence, or both? Trends Parasitol 19: 19-22.
15. Guidelines Subcommittee (1999) World Health Organization - International Society of Hypertension. Guidelines for the management of hypertension. J Hypertens 17: 151-183.
16. Hartz AJ, Anderson AJ, Brooks HL, Manley JC, Parent GT & Barboriak J (1984) The association of smoking with cardiomyopathy. N Engl J Med 311: 1201-1206.
17. Higuchi ML, De Morais F, Pereira-Barreto AC, Lopes EA, Stolf N, Bellotti G & Pileggi F (1987) The role of active myocarditis in the development of heart failure in chronic Chagas disease:a study based on endomyocardial biopsies. Clin Cardiol 10: 665-670.
18. Kalil J & Cunha-Neto E (1996) Autoimmunity in Chagas disease cardiomyopathy:fulfilling the criteria at last? Parasitol Today 12: 396-399.
19. Kirchhoff LV (1993) American trypanosomiasis (Chagas' disease). A tropical disease now in the United States. N Engl J Med 329: 639-644.
20. Kohriyama T, Ariga T & Yu RK (1988) Preparation and characterization of antibodies against sulfated glucuronic acid-containing glycosphingolipid. J Neurochem 51: 869-877.
21. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
22. Leon JS & Engman DM (2001) Autoimmunity in Chagas heart disease. Int J Parasitol 31: 555-561.
23. Levitus G, Hontebeyre-Joskowicz M, Van Regenmortel M & Levin MJ (1991) Humoral autoimmune response to ribosomal P proteins in chronic Chagas' heart disease. Clin Exp Immunol 85: 413-417.
24. Lopez Bergami P, Scaglione J & Levin MJ (2001) Antibodies against the carboxylterminal end of the Trypanosoma cruzi ribosomal P proteins are pathogenic. FASEB J 15: 2602-2612.
25. Marcipar I, Olivares ML, Robles L, Dekanty A, Marcipar A & Silber A (2004) The diagnostic performance of recombinant Trypanosoma cruzi ribosomal P2β protein is influenced by its expression system. Protein Expres Purif 34: 1-7.
26. Martinez J, Campetella O, Frasch ACC & Cazzulo JJ (1991) The major cysteine proteinase (cruzipain) from Trypanosoma cruzi is antigenic in human infections. Infect Immun 59: 4275-4277.
27. Masuda MO, Levin M, De Oliveira SF, Dos Santos Costa PC, Bergami PL, Dos Santos Almeida NA, Pedrosa RC, Ferrari I, Hoebeke J & Campos de Carvalho AC (1998) Functionally active cardiac antibodies in chronic Chagas' disease are specifically blocked by Trypanosoma cruzi antigens. FASEB J 12: 1551-1558.
28. Montamat E, D'oro G, Gallerano R, Sosa R & Blanco A (1996) Characterization of Trypanosoma cruzi population by zymodemes:correlation with clinical picture. Am J Trop Med Hyg 55: 625-628.
29. Morrot A, Strickland DK, Higuchi ML, Reis M, Pedrosa R & Scharfstein J (1997) Human T cell responses against the major cysteine proteinase (cruzipain) of Trypanosoma cruzi: role of the multifunctional alpha 2-macroglobulin receptor in antigen presentation by monocytes. Int Immunol 9: 825-834.
30. Novo S, Barbagallo M, Abrignani MG, Nardi E, Di Maria GU, Longo B, Mistretta A & Strano A (1997) Increased prevalence of cardiac arrhythmias and transient episodes of myocardial ischemia in hypertensives with left ventricular hypertrophy but without clinical history of coronary heart disease. Am J Hypertens 10: 843-851.
31. Petry K, Nudelman E, Eisen H & Hakomori SI (1988) Sulfated lipids represent common antigens on the surface of Trypanosoma cruzi and mammalian tissues. Mol Biochem Parasitol 30: 113-121.
32. Piano MR & Schwertz DW (1994) Alcoholic heart disease: a review. Heart Lung 23: 3-17.
33. Pontes-De-Carvalho L, Santana CC, Soares MB, Oliveira GG, Cunha-Neto E & Ribeiro-Dos-Santos R (2002) Experimental chronic Chagas' disease myocarditis is an autoimmune disease preventable by induction of immunological tolerance to myocardial antigens. J Autoimmunity 18: 131-138.
34. Reis MM, Higuchi ML, Benvenuti LA, Aiello VD, Gutierrez PS, Bellotti G & Pileggi F (1997) An in situ quantitative immunohistochemical study of cytokines and IL-2R+ in chronic human chagasic myocarditis:correlation with the presence of myocardial Trypanosoma cruzi antigens. Clin Immunol Immunopathol 83: 165-172.
35. Risso MG, Garbarino GB, Mocetti E, Campetella O, Gonzalez Cappa SM, Buscaglia CA & Leguizamon MS (2004) Differential expression of a virulence factor, the trans-sialidase, by the main Trypanosoma cruzi phylogenetic lineages. J Infect Dis 189: 2250-2259.
36. Roberts DD (1991) Sulfatide-binding proteins. Chem Phys Lipids 42: 173-183.
37. Saida K, Saida K, Brown MJ & Silberberg DH (1979) In vivo demyelination induced by intraneural injection of anti-galactocerebroside serum. A morphological study. Am J Pathol 95: 99-116.
38. Sharfstein J, Schechter M, Senna M, Peralta JM, Mendonca-Previato L & Miles MA (1986) Trypanosoma cruzi:characterization and isolation of a 57/51,000 m.w. surface glycoprotein (GP57/51) expressed by epimastigotes and bloodstream trypomastigotes. J Immunol 137: 1336-1341.
39. Storino R (1994) Chagas crónico. Enfermedad de Chagas (Storino R & Miles J, eds), pp. 247-265. Doyma Argentina, Buenos Aires, Argentina.
40. Szarfman A, Terranova VP, Rennard SI, Foidart JM, Fatima Lima M, Scheinman JI & Martin GR (1982) Antibodies to laminin in Chagas' disease. J Exp Med 155: 1161-1171.
41. Towbin H, Rosenfelder G, Wieslander J, Avila JL, Rojas M, Szarfman A, Esser K, Nowack H & Timpl R (1987) Circulating antibodies to mouse laminin in Chagas disease, American cutaneous leishmaniasis, and normal individuals recognize terminal galactosyl (alpha 1-3) galactose epitopes. J Exp Med 166: 419-432.
42. World Health Organization (1984) Cardiomiopatías. Serie de Informes Técnicos, 697, pp. 47-55.World Health Organization, Geneva, Switzerland.